All News

New view of mutations informs disease risk, treatment response

A transcontinental research effort led by scientists from Vanderbilt University Medical Center and the University of Michigan has upended some long-standing assumptions about mutations — how often they occur, what causes them and what they do.

Lovly elected to American Association for Cancer Research board

Christine Lovly, MD, PhD, has been elected to the American Association for Cancer Research board of directors.

Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.

Neural networks probe proteins

A machine learning method based on neural networks outperformed a mutational scanning model at identifying disease-causing mutations in an Alzheimer’s disease protein, suggesting the method could be useful for facilitating therapeutic design.

Diabetes drugs associated with fewer adverse cardiac events in older veterans: study

Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.

Improved imaging for kidney disease

Vanderbilt researchers identified optimal MRI parameters for estimating the severity of polycystic kidney disease, a common inherited disorder that can lead to end-stage renal failure.

1 101 102 103 104 105 144